Clinical trials: PD-L1
Multiple Myeloma
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free…
- Trial name
- NCT02576977
- Testing
- Pembrolizumab, Pomalidomide, Dexamethasone
- Volunteers
- 251 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients…
- Trial name
- NCT05746481
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Liza Villaruz, MD
Endometrial Cancer
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy.
- Trial name
- POD1UM-204 (NCT04463771)
- Testing
- retifanlimab, epacadostat, pemigatinib
- Where
- 65 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Incyte Corporation
Urothelial Carcinoma
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.
In this Phase II study we investigate the benefit of cabozantinib treatment for patients with locally advanced or metastasized urothelial cell carcinoma who have been pre-treated with checkpoint inhibitors only (cohort 1) or who…
- Trial name
- CabUC (NCT04066595)
- Testing
- Cabozantinib
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Johannes Gutenberg University Mainz
Recurrent Glioblastoma, Recurrent Gliosarcoma
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent).
- Trial name
- NCT05039281
- Testing
- Atezolizumab, Cabozantinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Cancinoma (NPC)
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart, followed by treatment allocation…
- Trial name
- RAPID (NCT07904819)
- Testing
- Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM)
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
NSCLC
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC).
- Trial name
- NCT03562871
- Testing
- IO102, pembrolizumab (Keytruda), Carboplatin (Carboplatin Kabi)
- Where
- 13 sites in Germany, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- IO Biotech
Oesophageal Squamous Cell Carcinoma
NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma
The investigators will conduct a prospective, single-arm study to evaluate the safety and feasibility of neoadjuvant therapy with anti-PD-L1 antibody (SHR-1316, Hengrui Medicine) in patients with resectable esophageal squamous…
- Trial name
- NATION1907II (NCT04215471)
- Testing
- PD-L1 Antibody SHR-1316
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Oncology, NSCLC Stage IV
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer.
- Conditions
- Oncology, NSCLC Stage IV, NSCLC, Stage III
- Trial name
- LUNGVAC (NCT05344209)
- Testing
- UV1, Sagramostim, Anti-PD-1/PD-L1 treatment
- Where
- Norway
- Volunteers
- 138 people
- Sponsor
- Vestre Viken Hospital Trust
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
This is a phase 2, single-centre, randomized, multi-cohort trial of subjects with advanced Mismatch Repair Proficient Colorectal Cancer (MMRp-CRC), Pancreatic Adenocarcinoma (PA), and Leiomyosarcoma (LMS).
- Conditions
- Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
- Trial name
- DAPPER (NCT03851614)
- Testing
- Durvalumab, Olaparib, Cediranib
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Non-Small-Cell Lung, Carcinoma Breast
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of…
- Trial name
- NCT05603013
- Testing
- Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Urothelial Carcinoma
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
This is a single arm phase II study assessing the activity of atezolizumab in combination with carboplatin + gemcitabine or docetaxel compared to historical controls of chemotherapy only in metastatic or recurrent urothelial…
- Trial name
- NCT03737123
- Testing
- Carboplatin, Gemcitabine, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nabil Adra
Advanced Non-small Cell Lung Cancer
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy.
- Trial name
- NCT05001724
- Testing
- KN046, Lenvatinib, Docetaxel
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Stage IV Non-small Cell Lung Cancer
Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth
The investigators will develop a radiomics signature for immune checkpoint-induced pneumonitis in 40 patients with a pulmonary event under anti-PD1 or anti-PD-L1 (cases) and 40 patients without a pulmonary event under anti-PD1 or…
- Trial name
- NCT03305380
- Testing
- No interventions
- Where
- 2 sites in Netherlands
- Volunteers
- 637 people
- Sponsor
- Maastricht Radiation Oncology
Metastatic Non-small Cell Lung Cancer
Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Based on the use of the patient's natural defences, immunotherapy mobilizes the immune system to recognize and destroy cancer cells, and it has revolutionized the treatment of lung cancer.
- Trial name
- FENOTYPE (NCT05985330)
- Testing
- Measurement of FeNO
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Gastric Cancer
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
This is a randomized non-comparative, multicenter phase II study in patients with PD-L1 PD-L1 combined positive score (CPS) ≥5 advanced gastric cancer to evaluate the efficacy and safety of nivolumab and FOLFOX in combination…
- Trial name
- BIG (NCT06253611)
- Testing
- Nivolumab, FOLFOX regimen, EXL01
- Where
- 37 sites in France
- Volunteers
- 120 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Carcinoma, Non-Small-Cell Lung
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
The study is a prospective, open label, multicenter, single arm Phase II clinical trial, aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC patients with EGFR mutations and PD-L1 positive…
- Trial name
- TOPLINE (NCT06269211)
- Testing
- Toripalimab
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Ruijin Hospital
Gastroesophageal Adenocarcinoma
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
ARMANI-2/ENGIC8 is a randomized, open-label, phase III trial evaluating a switch maintenance strategy in patients with previously untreated, locally advanced unresectable or metastatic, HER2-negative and PD-L1-positive…
- Trial name
- ARMANI-2 (NCT07763171)
- Testing
- FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu
- Where
- 42 sites in Germany, Italy and 1 more
- Volunteers
- 244 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Hepatocellular Carcinoma
PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7
This is a retrospective study that retrospectively included patients with intermediate and advanced HCC beyond up to seven who received first-line treatment with PD-1/PD-L1 inhibitors and anti-angiogenic agents combined…
- Trial name
- NCT06423144
- Testing
- TACE/HAIC, PD-1/PD-L1 inhibits and anti-angiogenic agents
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Solid Tumor, Adult
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors.
- Trial name
- NCT07159828
- Testing
- AXN-2510
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Axion Bio, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.